Combining random mutagenesis, structure-guided design and next-generation sequencing to mitigate polyreactivity of an anti-IL-21R antibody-Reference-Cited by-同舟云学术

Combining random mutagenesis, structure-guided design and next-generation sequencing to mitigate polyreactivity of an anti-IL-21R antibody

Published:2021-01-01 Issue:1 Volume:13 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Campbell Sharon M.¹,DeBartolo Joseph²,Apgar James R.²,Mosyak Lydia²,McManus Virginie¹,Beyer Sonia¹,Bennett Eric M.²,Lambert Matthew¹,Cunningham Orla¹^ORCID

Affiliation:

1. Biomedicine Design, Pfizer, Dublin, Ireland

2. Biomedicine Design, Pfizer, Cambridge, MA, USA

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2021.1883239

Reference41 articles.

1. A Fully Human, Allosteric Monoclonal Antibody That Activates the Insulin Receptor and Improves Glycemic Control

2. Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a Fab-phage display library

3. Towards the Design of an Antibody that Recognises a Given Protein Epitope

4. Directing phage selections towards specific epitopes

5. CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Binding Promiscuity of Therapeutic Factor VIII;Thrombosis and Haemostasis;2024-07-01

2. Human-murine chimeric autoantibodies with high affinity and specificity for systemic sclerosis;Frontiers in Immunology;2023-06-16

3. Non-specificity as the sticky problem in therapeutic antibody development;Nature Reviews Chemistry;2022-11-14

4. Reconstruction of full antibody sequences in NGS datasets and accurate VL:VH coupling by cluster coordinate matching of non-overlapping reads;Computational and Structural Biotechnology Journal;2022

5. Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns;mAbs;2021-01-01